AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Published: 16 November 2023
-
Views:
1855
-
Likes:
7
-
Views:
1855
-
Likes:
7
-
Up Next -
15m 26sPart 1 | Session 10 ARIES HM3: Avoidance of Aspirin with LVAD Devices
-
14m 58sPart 1 | Session 1 ORBITA-2: PCI for Stable Angina Rasha Al-Lamee, Nazli Okumus, Christopher Rajkumar
-
11m 47sPart 1 | Session 2 SELECT: Effects of Semaglutide on Heart Disease & Stroke in Obese Patients A Michael Lincoff , Ahmed Ghoneem
-
16m 5sPart 1 | Session 3 MINT: Myocardial Ischaemia & Transfusion Nazli Okumus, Jeffrey L Carson
-
11m 41sPart 1 | Session 4 KARDIA-1: ALN-AGT01 in Patients With Mild-to Moderate Hypertension George L Bakris, Sukriti Banthiya
-
8m 35sPart 1 | Session 5 CordiO App: Speech Analysis to Detect Worsening HF in ADHF Patients Hanad Bashir, William T Abraham
-
14m 32sPart 1 | Session 6 AHA23: Presidential Advisory on Cardiovascular-Kidney-Metabolic Health Ramy Doss, Chiadi Ndumele
-
10m 36sPart 1 | Session 7 AZALEA-TIMI 71: Abelcibab Vs Rivaroxaban in Patients with AF Naima Maqsood, Christian Ruff
-
9m 14sPart 1 | Session 8 An Extended Duration Short-Interfering RNA Targeting Lp(a) Maryam Barkhordarian, Steven E Nissen
Overview
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.
These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
More from this programme
Part 1
Radcliffe & Cardionerds @AHA23
About the episode
AHA 2023 — Dr Naima Maqsood, CardioNerds ambassador (Temple University Hospital, US) interviews investigator, Dr Jeff Healey (McMaster University, CA) to outline the findings from a phase 4 trial of apixaban to reduce thromboembolism in patients with subclinical atrial fibrillation (AF).
ARTESiA (NCT01938248) aims to determine if apixaban in combination with aspirin can reduce the instance of ischemic stroke and embolism in patients with device-detected subclinical AF.
Patients will be randomized to receive either apixaban or aspirin. Apixaban dose will be 5 mg twice daily. Those assigned to aspirin will receive a dose of 81 mg daily. This is an event-driven study, and will continue until 248 patients out of 4012 participants have experienced a clinical event.
Apixaban reduced the risk of stroke or systemic embolism in patients with subclinical atrial fibrillation, with fatal and disabling strokes reduced by 49%. An increase in major bleeding was observed with apixaban, however, there was no increase found in fatal or intracranial bleeding detected. This suggests that anticoagulation should be considered for patients with subclinical atrial fibrillation who have additional stroke risk factor.
Recorded on-site at AHA 23, Philadelphia.
Supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs.
Faculty Biographies
Naima Maqsood
Naima Maqsood is a cardiology fellow at Temple University Hospital, Philadelphia. She graduated from the Aga Khan University Medical College in Pakistan. She completed Internal Medicine residency at Temple where she was part of the Medical Education Track. Her passions include electrophysiology, hemodynamics, exercise physiology and Medical Education. She is keen on pursuing a career in Cardiac Electrophysiology. Outside the hospital, she enjoys watching horror movies, learning about astrophysics and stargazing.
Jeff Healey
Jeff Healey serves as the director of arrhythmia services and holds the position of associate professor of medicine at McMaster University in Hamilton, Ontario, Canada. As a clinical trialist and member of the Population Health Research Institute, Dr. Healey completed his clinical training in cardiology and electrophysiology at the University of Ottawa Heart Institute. He furthered his academic pursuits by obtaining a Master’s degree in health research methodology at McMaster University.
Engaging in diverse clinical activities, Dr. Healey is proficient in catheter ablation and pacemaker/ICD implantation. His research endeavors focus on conducting randomized clinical trials and large registries in the fields of cardiac arrhythmias and cardiac devices. His primary research interest lies in studying the impact of risk factors and risk factor modification on the development of atrial fibrillation and its associated complications, particularly stroke.
Dr. Healey gained…
Comments